Abstract
EEG biomarkers of early auditory information processing, such as mismatch negativity (MMN) and P3a, have been instrumental in understanding cognitive deficits in schizophrenia (SZ). However the impact of medication factors, specifically anticholinergic medication burden, have not been assessed. Multiple reports have described that anticholinergic medication burden (ACB) is substantial in SZ, stems from multiple different classes of medications, and impairs cognitive functioning across multiple domains. We therefore investigated the impact of anticholinergic medication burden on MMN/P3a in a large cohort of SZ outpatients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
